Keyword Analysis & Research: cassava sciences
Keyword Research: People who searched cassava sciences also searched
Search Results related to cassava sciences on Search Engine
-
Cassava Sciences | Cassava Sciences, Inc.
https://www.cassavasciences.com/
WebWe Innovate. We are a clinical-stage biopharmaceutical company focused on neuroscience. We translate novel scientific insights into new medicines. That’s a drastic challenge. Our work is complex, risky, labor-intensive, persistent and expensive. And it’s what we love to …
DA: 43 PA: 94 MOZ Rank: 11
-
Science | Cassava Sciences, Inc.
https://www.cassavasciences.com/science
WebSavaDx is our blood-based investigational diagnostic to detect Alzheimer’s disease. The goal of SavaDx is to make the detection of Alzheimer’s disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.
DA: 91 PA: 92 MOZ Rank: 33
-
Cassava Sciences - Wikipedia
https://en.wikipedia.org/wiki/Cassava_Sciences
WebCassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was founded in 1998 by chief executive officer and president Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019.
DA: 22 PA: 36 MOZ Rank: 14
-
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam …
https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-initiates-phase-3-efficacy-trial-simufilam
WebOct 06, 2021. First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s Disease. A Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimer’s Disease.
DA: 61 PA: 59 MOZ Rank: 86
-
PRESS RELEASES | Cassava Sciences, Inc.
https://www.cassavasciences.com/press-releases
WebNov 6, 2023 · Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates. February 7, 2024. No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months. January 5, 2024. Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders.
DA: 63 PA: 53 MOZ Rank: 57
-
Investor Relations | Cassava Sciences, Inc.
https://www.cassavasciences.com/investor-relations
WebCassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs. Presentations. Cassava Corporate Presentation – First Quarter 2024. Warrant Distribution Q&A – Updated January 3, 2024. Warrant Prospectus Supplement (as filed with SEC) Financial Information. SEC Filings. Annual Reports. Press Releases. View all.
DA: 36 PA: 58 MOZ Rank: 48
-
Cassava Sciences Announces Science Publication That Confirms …
https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-announces-science-publication-confirms
WebSep 11, 2023 · Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease. Sep 11, 2023. New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.
DA: 41 PA: 65 MOZ Rank: 83
-
Simufilam | Cassava Sciences, Inc.
https://www.cassavasciences.com/simufilam
WebOur science is based on stabilizing a critical protein in the brain. Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.
DA: 24 PA: 83 MOZ Rank: 39
-
Cassava Sciences Completes Patient Enrollment for Pivotal …
https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-completes-patient-enrollment-pivotal-phase-3
WebAUSTIN, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer’s patients are enrolled in this 12-month trial. A second Phase 3 clinical trial with a target enrollment ...
DA: 99 PA: 39 MOZ Rank: 89
-
Cassava Sciences Reports Full-year 2021 Financial Results and …
https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-reports-full-year-2021-financial-results-and
WebDec 31, 2021 · AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.
DA: 62 PA: 43 MOZ Rank: 30
